TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35841053

Group type: EXPERIMENTAL
Intervention: Preseason assessments of eccentric hamstring strength, on-field sprinting biomechanics, and muscle-tendon volumes using MRI.
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Clinical assessments and MRI examinations post-injury and after rehabilitation.
Number of subjects: 1200
Study: 35841086

Group type: EXPERIMENTAL
Intervention: Standardized psychomotor assessment
Number of subjects: 25
Study: 35841307

Group type: EXPERIMENTAL
Intervention: Local therapy (initial primary surgery in 7 cases)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Systemic therapy (5 patients)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 11
Study: 35841429

Group type: EXPERIMENTAL
Intervention: YMD-CHO
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: YMD-F
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control-CHO
Number of subjects: 8
Study: 35841456

Group type: EXPERIMENTAL
Intervention: Button battery ingestion
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Symptoms related to esophageal impaction
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Button batteries > 15 mm
Number of subjects: 415
Study: 35841526

Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 1 (metachronous mHSPC) - 35% of patients developed metastases before becoming castration resistant
Number of subjects: 2859

Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 2 - 10% of patients developed castration resistance before metastases
Number of subjects: 2859

Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 3 - 27% of patients developed metastases and castration resistance within 4 months
Number of subjects: 2859

Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 4 (de novo mHSPC) - 28% of patients
Number of subjects: 2859
Study: 35842005

Group type: EXPERIMENTAL
Intervention: High lipid content segments
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Segments with increasing lipidic content and plaque burden
Number of subjects: 1269

Group type: EXPERIMENTAL
Intervention: Segments with maxLCBI
Number of subjects: 1269
Study: 35842202

Group type: EXPERIMENTAL
Intervention: Iliac branch endoprosthesis (IBE) device implantation
Number of subjects: 63
Study: 35842229

Group type: EXPERIMENTAL
Intervention: HPV incident infections
Number of subjects: 6322

Group type: EXPERIMENTAL
Intervention: Incident oncogenic HPV infections (HPV16/18/31/33/35/39/45/51/52/56/58/59)
Number of subjects: 6322

Group type: EXPERIMENTAL
Intervention: HPV16/18
Number of subjects: 6322

Group type: EXPERIMENTAL
Intervention: HPV31/33/45/52/58
Number of subjects: 6322

Group type: EXPERIMENTAL
Intervention: 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable types
Number of subjects: 6322

Group type: EXPERIMENTAL
Intervention: HPV prevalences
Number of subjects: 6322
Study: 35842320

Group type: EXPERIMENTAL
Intervention: NRN Follow-up Study Group interventions
Number of subjects: 0
Study: 35842352

Group type: EXPERIMENTAL
Intervention: Passive leg raising
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 270
Study: 35842563

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) with Sonazoid
Number of subjects: 26
Study: 35842567

Group type: EXPERIMENTAL
Intervention: Trilaciclib (200 or 240 mg/m)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Trilaciclib (200 or 240 mg/m) with rifampin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Trilaciclib (200 or 240 mg/m) with itraconazole
Number of subjects: 77
Study: 35843046

Group type: EXPERIMENTAL
Intervention: Balanced solutions (Plasma Lye 148)
Number of subjects: 10490

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10490

Group type: EXPERIMENTAL
Intervention: Balanced solutions (Plasma Lye 148) in traumatic brain injury patients
Number of subjects: 10490

Group type: COMPARATOR
Intervention: 0.9% saline in traumatic brain injury patients
Number of subjects: 10490
Study: 35843096

Group type: EXPERIMENTAL
Intervention: Sputum rheology assessment using Rheomuco® rheometer
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sputum rheology assessment in asthma patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Correlation of rheology with mucin concentrations
Number of subjects: 48
Study: 35843439

Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 21
Study: 35843546

Group type: EXPERIMENTAL
Intervention: AB680 (CD73 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: palbociclib (CDK4/6 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of AB680 and palbociclib
Number of subjects: 0
Study: 35843549

Group type: EXPERIMENTAL
Intervention: Rapid recovery protocol (RP) with local infiltration of levo-bupivacaine and supervised ambulation 4-6 hours after surgery
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group with femoral nerve block with levo-bupivacaine and ambulation after drain removal
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Rapid recovery protocol (RP)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study: 35843615

Group type: EXPERIMENTAL
Intervention: Highly sensitive troponin assay
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Local troponin testing results
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Clinical grounds diagnosis
Number of subjects: 1500
Study: 35843739

Group type: EXPERIMENTAL
Intervention: Sapanisertib 3 or 4 mg, Serabelisib 200 mg on days 2-4, 9-11, 16-18 and 23-25 with Paclitaxel 80 mg/m2 on days 1, 8 and 15 every 28 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sapanisertib, Serabelisib, and Paclitaxel
Number of subjects: 19
Study: 35843746

Group type: EXPERIMENTAL
Intervention: Postoperative anaemia
Number of subjects: 2983
Study: 35843943

Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation (iTBS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation
Number of subjects: 10
Study: 35844014

Group type: EXPERIMENTAL
Intervention: Bone marrow concentrate (BMC) injections
Number of subjects: 12780
Study: 35844029

Group type: EXPERIMENTAL
Intervention: Lucitanib (5-30 mg daily doses)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Lucitanib formulation (film-coated tablet or hard gelatin capsule)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Concomitant medications (CYP3A4 inhibitors/inducers, CYP2C8 or P-glycoprotein inhibitors, proton pump inhibitors)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Ongoing clinical study of lucitanib
Number of subjects: 403
Study: 35844042

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 748
Study: 35844168

Group type: COMPARATOR
Intervention: OROS-MPH (osmotic-release oral system methylphenidate)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Omega-3 with risperidone and usual anti-seizure medication (ASM)
Number of subjects: 94
Study: 35844232

Group type: EXPERIMENTAL
Intervention: Neuroepo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 35844693

Group type: EXPERIMENTAL
Intervention: SKY92 molecular signature analysis
Number of subjects: 147
Study: 35844773

Group type: EXPERIMENTAL
Intervention: Topical ENERGI-F703 gel applied twice daily for 12 weeks or until complete ulcer closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel applied twice daily for 12 weeks or until complete ulcer closure
Number of subjects: 0
Study: 35845005

Group type: EXPERIMENTAL
Intervention: VTd-mod (100 mg daily thalidomide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VTd-label (escalating thalidomide dose up to 200 mg daily)
Number of subjects: 0
Study: 35845063

Group type: EXPERIMENTAL
Intervention: Left Ventricular Diastolic Dysfunction (LVDD)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lung ultrasound score (LUSS)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LVDD
Number of subjects: 54
Study: 35845292

Group type: EXPERIMENTAL
Intervention: Rituximab added to venetoclax after progression on venetoclax monotherapy
Number of subjects: 10
Study: 35845461

Group type: EXPERIMENTAL
Intervention: Incidence rate of new suicide attempts during 3 months of follow-up
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Socio-demographic, clinical and biological assessments including blood and hair cortisol levels, plasma pro- and mature BDNF isoforms proportion
Number of subjects: 200
Study: 35845530

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment for LARC
Number of subjects: 302
Study: 35845797

Group type: EXPERIMENTAL
Intervention: Multispecies synbiotic supplement (once daily for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 61
Study: 35845810

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeDiet) group
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 35845857

Group type: EXPERIMENTAL
Intervention: Precision prevention materials incorporating genetic testing
Number of subjects: 920

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 920
Study: 35846031

Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122) 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m2
Number of subjects: 0
Study: 35846039

Group type: EXPERIMENTAL
Intervention: Random forest model with COO subgroups
Number of subjects: 1263

Group type: COMPARATOR
Intervention: International prognostic index (IPI)
Number of subjects: 1263
Study: 35846096

Group type: EXPERIMENTAL
Intervention: Oral selinexor plus low-dose dexamethasone (Sel-dex)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Other available therapies (control group)
Number of subjects: 186
Study: 35846097

Group type: EXPERIMENTAL
Intervention: VTd-mod (bortezomib, thalidomide 100 mg/day, dexamethasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-VTd (bortezomib, thalidomide, dexamethasone with daratumumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VTd-label (bortezomib, thalidomide 200 mg/day, dexamethasone)
Number of subjects: 0
Study: 35846215

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician's choice of treatment (PCT)
Number of subjects: 0
Study: 35846221

Group type: EXPERIMENTAL
Intervention: CC-122 plus rituximab
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CC-223 and CC-292 combinations
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CC-122
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall treatment arms
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 106
Study: 35846226

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 37.5 mg
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study: 35846272

Group type: EXPERIMENTAL
Intervention: Treatment of hyperaldosteronism
Number of subjects: 57
Study: 35846333

Group type: EXPERIMENTAL
Intervention: Machine learning methods (random forest, RF)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: Machine learning methods (support vector machine, SVM)
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: External validation using RF method
Number of subjects: 929

Group type: EXPERIMENTAL
Intervention: External validation using SVM method
Number of subjects: 929
Study: 35847080

Group type: EXPERIMENTAL
Intervention: Hirschsprung-associated enterocolitis (HAEC) group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Hirschsprung's disease without enterocolitis (HD) group
Number of subjects: 103
Study: 35847221

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (onabotA)
Number of subjects: 0
Study: 35847524

Group type: EXPERIMENTAL
Intervention: Remote visits via phone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Remote visits via videochat
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional outpatient visits
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Overall cohort satisfaction (physician satisfaction)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional visits (physician satisfaction)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Phone visits (physician satisfaction)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Video visits (physician satisfaction)
Number of subjects: 45
Study: 35847727

Group type: EXPERIMENTAL
Intervention: Posttransplant bendamustine (PT-BEN)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Posttransplant cyclophosphamide (PT-CY)
Number of subjects: 3
Study: 35847807

Group type: EXPERIMENTAL
Intervention: Tapered cuff tracheal tube
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional cylindrical high-volume low-pressure cuff (control)
Number of subjects: 80
Study: 35847877

Group type: EXPERIMENTAL
Intervention: Gallium68-fibroblast-activation protein inhibitor
Number of subjects: 25
Study: 35848424

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35848462

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35848614

Group type: EXPERIMENTAL
Intervention: ISIKOK-19 T-cell therapy
Number of subjects: 9
Study: 35848622

Group type: EXPERIMENTAL
Intervention: Minocycline treatment
Number of subjects: 96
Study: 35848990

Group type: EXPERIMENTAL
Intervention: 1.25% pilocarpine ophthalmic solution eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35848991

Group type: EXPERIMENTAL
Intervention: AHCL system after temporary target (TT) use
Number of subjects: 60

Group type: COMPARATOR
Intervention: HCL system after temporary target (TT) use
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AHCL system during non-TT periods
Number of subjects: 60

Group type: COMPARATOR
Intervention: HCL system during non-TT periods
Number of subjects: 60
Study: 35849186

Group type: EXPERIMENTAL
Intervention: Distal Ulna Locking Plate (DUL)
Number of subjects: 20
Study: 35849430

Group type: EXPERIMENTAL
Intervention: EHR-driven process for identifying unpaid caregivers
Number of subjects: 12212

Group type: EXPERIMENTAL
Intervention: Veterans characteristics associated with having unpaid caregivers
Number of subjects: 12212
Study: 35849756

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard bupivacaine
Number of subjects: 76
Study: 35849791

Group type: EXPERIMENTAL
Intervention: Venetoclax plus Gilteritinib
Number of subjects: 61
Study: 35850123

Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP) with rifampicin
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 1199
Study: 35850444

Group type: EXPERIMENTAL
Intervention: Low baseline plasma L-arginine (ARG) levels (<42 μM)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: High baseline plasma L-arginine (ARG) levels
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Low baseline plasma L-arginine (ARG) levels
Number of subjects: 373
Study: 35850660

Group type: EXPERIMENTAL
Intervention: TAS Test
Number of subjects: 10000
Study: 35850705

Group type: EXPERIMENTAL
Intervention: EVD based CSF-Hb
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: LD based CSF-Hb
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: CSF-Hb
Number of subjects: 250
Study: 35850765

Group type: EXPERIMENTAL
Intervention: Prediabetes (preDM)
Number of subjects: 544
Study: 35850771

Group type: EXPERIMENTAL
Intervention: Tidal volume challenge (TVC) with pulse pressure variation (PPV) monitoring
Number of subjects: 58
Study: 35850782

Group type: EXPERIMENTAL
Intervention: XR-NTX treatment
Number of subjects: 19
Study: 35851282

Group type: EXPERIMENTAL
Intervention: Automated strain assessment (GLS)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Automated strain assessment (GCS)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Manual strain assessment (GLS)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Manual strain assessment (GCS)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Automated functional analyses (GLS)
Number of subjects: 1095
Study: 35851316

Group type: EXPERIMENTAL
Intervention: Second tertile of Lp(a) concentrations
Number of subjects: 3059

Group type: EXPERIMENTAL
Intervention: Third tertile of Lp(a) concentrations
Number of subjects: 3059
Study: 35851408

Group type: EXPERIMENTAL
Intervention: ECP-ligand peptide (E5)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 94

Group type: COMPARATOR
Intervention: GERD patients
Number of subjects: 94
Study: 35851430

Group type: EXPERIMENTAL
Intervention: 6-week online singing intervention (Melodies for Mums - M4M)
Number of subjects: 120
Study: 35852004

Group type: EXPERIMENTAL
Intervention: Durvalumab monotherapy (Arm D)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with lenalidomide ± rituximab (Arm A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with ibrutinib (Arm B)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with rituximab ± bendamustine (Arm C)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Durvalumab (monotherapy or combination)
Number of subjects: 106
Study: 35852094

Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) at 2 mA for 30 minutes daily for 4 months
Number of subjects: 8
Study: 35852104

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35852275

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training for 12 weeks
Number of subjects: 70
Study: 35852359

Group type: EXPERIMENTAL
Intervention: Ultraprocessed food intake (quartile 4 vs. 1)
Number of subjects: 1948

Group type: EXPERIMENTAL
Intervention: Ultraprocessed food intake
Number of subjects: 1948
Study: 35852425

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Micro-US
Number of subjects: 94
Study: 35852431

Group type: EXPERIMENTAL
Intervention: DCFPyL PET/CT in newly diagnosed prostate cancer (sample 1)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: DCFPyL PET/CT in biochemically recurrent prostate cancer (sample 2)
Number of subjects: 184
Study: 35852544

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (specifically Random Forests)
Number of subjects: 3782

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (using only the eight most important features)
Number of subjects: 3782

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (general prediction)
Number of subjects: 3782
Study: 35852619

Group type: EXPERIMENTAL
Intervention: Modified DEP regimen as induction therapy
Number of subjects: 28
Study: 35852656

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (4,000 IU or 2,000 IU per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 35852831

Group type: EXPERIMENTAL
Intervention: AI-based ASD diagnosis aid integrated into the ECHO Autism STAT diagnosis model
Number of subjects: 41
Study: 35852839

Group type: EXPERIMENTAL
Intervention: AG-920, a topical ocular anesthetic
Number of subjects: 0
Study: 35852876

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study: 35853003

Group type: EXPERIMENTAL
Intervention: Placental T2* measurements using BOLD-MRI
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Placental T2* percentile
Number of subjects: 316
Study: 35853188

Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine (qHPV; HPV6/11/16/18)
Number of subjects: 3403
Study: 35853530

Group type: EXPERIMENTAL
Intervention: Omnipod® 5 Automated Insulin Delivery (AID) System
Number of subjects: 115
Study: 35853681

Group type: EXPERIMENTAL
Intervention: First-line (1L) erlotinib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: First-line (1L) afatinib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: First-line (1L) gefitinib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Testing for T790M mutation after progression on 1L treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Second-line (2L) treatment with osimertinib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Real-world progression free survival on 1L EGFR TKIs
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall survival on 1L EGFR TKIs
Number of subjects: 120
Study: 35853728

Group type: EXPERIMENTAL
Intervention: Recombinant Erythropoietin for Protection of Infant Renal Disease (REPAIReD) study
Number of subjects: 832

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 832
Study: 35853745

Group type: EXPERIMENTAL
Intervention: Pregnant WWE
Number of subjects: 241
Study: 35853750

Group type: EXPERIMENTAL
Intervention: Self-reflection (measured via the reflective pondering subscale of the Rumination Response Scale)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Self-reflection
Number of subjects: 259
Study: 35853863

Group type: EXPERIMENTAL
Intervention: MVA-MERS-S booster vaccination
Number of subjects: 0
Study: 35853972

Group type: EXPERIMENTAL
Intervention: Nurse-led health dialogue focusing on lifestyle habits, anthropometric measurements, and blood samples.
Number of subjects: 64
Study: 35853994

Group type: EXPERIMENTAL
Intervention: ERY974 at a starting dose of 3.0 ng/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERY974 at 4.9 ng/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERY974 at 0.1 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ERY974 at 3.2 ng/kg
Number of subjects: 0
Study: 35854086

Group type: EXPERIMENTAL
Intervention: SharePR parent-report measure of caregiver-infant reading quality
Number of subjects: 207
Study: 35854137

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) injection
Number of subjects: 63
Study: 35854274

Group type: EXPERIMENTAL
Intervention: Audiological assessments in patients with GACI
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Audiometric configurations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cranial CT imaging
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Recurrent episodes of otitis media (ROM)
Number of subjects: 19
Study: 35854275

Group type: EXPERIMENTAL
Intervention: Non-invasive liver stiffness measurement (LSM) by vibration-controlled transient elastography
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Health economic evaluation
Number of subjects: 30000